Facebook (FB) PT Raised to $120 at Pivotal Research Following 4Q

Facebook (FB) PT Raised to $195 at Piper Jaffray

Piper Jaffray analyst Michael Olson raised the price target on Facebook (NASDAQ: FB) to $195.00 (from $190.00) while maintaining a Overweight rating following the company's 4Q. Revenue growth came in at 30% y/y (vs. 33% in Q3'18) or $16.9B vs. consensus at $16.4B. GAAP... More

Facebook (FB) PT Raised to $190 at Morgan Stanley

Morgan Stanley analyst Brian Nowak raised the price target on Facebook (NASDAQ: FB) to $190.00 (from $175.00) while maintaining a Overweight rating following the company's 4Q earnings report. FB posted stronger revenue, EBIT, EPS and engagement, and results showed evidence that Stories is starting to drive... More

Facebook (FB) PT Raised to $195 at Oppenheimer

Oppenheimer analyst Jason Helfstein raised the price target on Facebook (NASDAQ: FB) to $195.00 (from $185.00) while maintaining a Outperform rating.

Helfstein commented, "Increasing target from $185 to $195 and maintaining Outperform rating, suggesting 15% upside potential from after-hours trading (+12%). Usage trends remain solid, as US... More

Facebook (FB) PT Raised to $195 at Macquarie Following 4Q Report

Macquarie analyst Benjamin Schachter raised the price target on Facebook (NASDAQ: FB) to $195.00 (from $190.00) while maintaining a Outperform rating following the company's 4Q earnings report. 4Q revenues and EPS were 3.9% and $0.34 above Macquarie's expectations, respectively.

The bottom line is that... More

KeyBanc Reiterates Overweight on Facebook (FB) Following 4Q

KeyBanc analyst, Andy Hargreaves, reiterated an Overweight rating and $195.00 price target on Facebook (NASDAQ: FB) following the company's 4Q. Total user growth remained remarkably stable, up 191M MAU in the quarter, which was in line with expectations. Ad revenue of $16.6B was 2% above estimates of... More

Facebook (FB) PT Raised to $195 at JMP Securities Following 4Q

JMP Securities analyst Ronald Josey raised the price target on Facebook (NASDAQ: FB) to $195.00 (from $176.00) while maintaining a Market Outperform rating following the company's 4Q earnings report. Revenue and profitability came in 3% and 7%, respectively, above consensus projections. EPS of $2.38 compares to consensus of... More

Facebook (FB) PT Raised to $200 at RBC Capital Following 4Q

RBC Capital analyst Mark Mahaney raised the price target on Facebook (NASDAQ: FB) to $200.00 (from $190.00) while maintaining a Outperform rating following the company's 4Q report. FB reported results above Street largely across the board. Q4 Revenue & GAAP Op Income came in well above... More

Facebook (FB) PT Raised to $200 at Canaccord Genuity

Canaccord Genuity analyst Michael Graham raised the price target on Facebook (NASDAQ: FB) to $200.00 (from $180.00) while maintaining a Buy rating.

Facebook (FB) PT Raised to $200 at Raymond James Following 4Q

Raymond James analyst Aaron Kessler raised the price target on Facebook (NASDAQ: FB) to $200.00 (from $180.00) while maintaining a Outperform rating following the company's 4Q earnings report. Total revenue of $16.9B (~3% above Street estimates) increased 30% y/y (33% y/y fxn vs. 34.5% y/y in 3Q).... More

Facebook (FB) PT Rises To $210 At Credit Suisse

Credit Suisse analyst, Stephen Ju, reiterated his Outperform rating on shares of Facebook (NASDAQ: FB) and raised his price target to $210 from $208 after the company reported revenue and EPS of $16.9b/$2.70 vs consensus of $16.4b/$2.52.

The analyst stated "The most important takeaway was the... More

Facebook (FB) PT Rises To $210 At Barclays On Improved Investor Confidence

Barclays analyst, Ross Sandler, reiterated his Overweight rating on shares of Facebook (NASDAQ: FB) and raised his price target to $210 from $180 after the company reported revenue & EPS that were 3% and 9% above consensus. Guidance for FY19 was also above consensus.

The analyst thinks this... More

Facebook (FB) PT Raised to $170 at UBS

UBS analyst Eric Sheridan raised the price target on Facebook (NASDAQ: FB) to $170.00 (from $160.00) while maintaining a Neutral rating.

Facebook's (FB) Positive Thesis Remains Intact - Baird

Baird analyst, Colin Sebastian, reiterated his Outperform rating on shares of Facebook (NASDAQ: FB) after the company reported solid top and bottom-line Q4 results. The executive team appeared to express more confidence in the business as revenue growth exceeded expectations consistent with the analyst's... More

Facebook (FB) PT Raised to $185 at Citi

Citi analyst Mark May raised the price target on Facebook (NASDAQ: FB) to $185.00 (from $175.00) while maintaining a Buy rating.

Facebook (FB) PT Raised to $172 at Nomura/Instinet

Nomura/Instinet analyst Mark Kelly raised the price target on Facebook (NASDAQ: FB) to $172.00 (from $148.00) while maintaining a Neutral rating.

Facebook (FB) PT Raised to $205 at BofA/Merrill Lynch

BofA/Merrill Lynch analyst Justin Post raised the price target on Facebook (NASDAQ: FB) to $205.00 (from $190.00) while maintaining a Buy rating.

Facebook (FB) PT Raised to $210 at Mizuho Securities

Mizuho Securities analyst James Lee raised the price target on Facebook (NASDAQ: FB) to $210.00 (from $200.00) while maintaining a Buy rating.

Facebook (FB) PT Raised to $120 at Pivotal Research, Remains Negative on the Business/Platform

Pivotal Research analyst Brian Wieser raised the price target on Facebook (NASDAQ: FB) to $120.00 (from $113.00) while maintaining a Sell rating.

The analyst says that while the Q4 report maybe be favorable, investors ought not to chance how they look at the... More

Facebook (FB) PT Raised to $195 at Macquarie

Macquarie raised its price target on Facebook (NASDAQ: FB) to $195.00 (from $190.00) while maintaining a Outperform rating.

After-Hours Movers 1/30: (FB) (FLEX) (NOW) Higher; (X) (PYPL) (MSFT) (more...)

Today's After-Hours Movers

SCYNEXIS, Inc. (NASDAQ: SCYX) 54% HIGHER; announced positive results from the first interim efficacy analysis of the ongoing FURI study. FURI is a Phase 3 open-label study evaluating oral ibrexafungerp as a salvage treatment in patients with difficult-to-treat mucocutaneous and invasive fungal infections that are refractory to or intolerant of currently available standards of care. An independent expert panel (Data Review Committee) assessed the efficacy of ibrexafungerp in the first 20 treated patients. Oral ibrexafungerp showed clinical benefits in 17 out of 20 patients, with 11 patients achieving a complete... More

Facebook (FB) said revenue growth will decelerate through 2019

On its call, Facebook (NASDAQ: FB) said revenue growth will decelerate through 2019, expenses to increase 40-50%

Facebook (FB) Tops Q4 EPS by 19c

Facebook (NASDAQ: FB) reported Q4 EPS of $2.38, $0.19 better than the analyst estimate of $2.19. Revenue for the quarter came in at $16.91 billion versus the consensus estimate of $16.4 billion.

Fourth Quarter and Full Year 2018 Operational and Other Financial Highlights

Speculative Call Buying Activity in Facebook (FB) Into Earnings Announcement Today After Market Close - Susquehanna

Susquehanna options strategist Alison Edwards notes speculative bullish positioning in Facebook (NASDAQ: FB), ahead of todays earnings report, as investors purchased 15k Feb 147/157.5 call spreads for $4.13 (expires 2/15) as well as 0k x 20k x 10k Feb1 152.5/155/157.5 call flies (expires this week). The implied earnings... More

Apple bans Facebook from tech tools for tracking teen browsing habits

By Stephen Nellis and Katie Paul

(Reuters) - Apple Inc (NASDAQ: AAPL) said on Wednesday it had banned Facebook Inc (NASDAQ: FB) from a program designed to let businesses control iPhones used by their employees, saying the social networking company had improperly used it to track the web-browsing habits of teenagers.

Apple offers what are known as certificates that let businesses have deep controls over iPhones, with the potential to remotely install apps, monitor app... More

Facebook (FB) option implied volatility increases into EPS and outlook

Facebook (NASDAQ: FB) February weekly call option implied volatility is at 110, February is at 61; compared to its 52-week range of 20 to 53 into the expected release of EPS after the bell on January 30. Call put ratio 1.4 calls to 1 put.

UPDATE: Apple (AAPL) revoked Facebook's (FB) iOS Developer Certificate - Cheddar

(Updated - January 30, 2019 9:51 AM EST)

Apple (NASDAQ: AAPL) revoked Facebook's (NASDAQ: FB) iOS Developer Certificate -... More

Rosenblatt Remains Buyer of Facebook (FB) Ahead of Earnings

Rosenblatt analyst Mark Zgutowicz maintains Buy on Facebook (NASDAQ: FB) price target of $206.00.

The analyst remains a buyer of the equity ahead of the expected disclosure of 1 billion or mote Stories DAUs and a stable P&L outlook.

He comments "While Stories... More

Facebook (FB) calls more active than puts into EPS and outlook

Facebook (NASDAQ: FB) February weekly call option implied volatility is at 100, February is at 51; compared to its 52-week range of 20 to 53 into the expected release of EPS after the bell on January 30. Call put ratio 1.5 calls to 1 put.

Facebook (FB) calls more active than puts into EPS and outlook

Facebook (NASDAQ: FB) February weekly call option implied volatility is at 100, February is at 51; compared to its 52-week range of 20 to 53 into the expected release of EPS after the bell on January 30. Call put ratio 1.5 calls to 1 put.

Active options: MSFT FB INTC TSLA F NFLX QCOM EBAY CRON SQ BABA

Active options: MSFT FB INTC TSLA F NFLX QCOM EBAY CRON SQ BABA

Options expected to have increasing volume: FB GE HON MCD QCOM

Options expected to have increasing volume: FB GE HON MCD QCOM

Facebook (FB) PT Lowered to $160 at MoffettNathanson

MoffettNathanson analyst Michael Nathanson lowered the price target on Facebook (NASDAQ: FB) to $160.00 (from $165.00) while maintaining a Neutral rating.

Facebook (FB) collecting data on teens in a very sketchy way - TechCrunch

Facebook (NASDAQ: FB) on watch as TechCrunch editor said the company has been collecting data on teens in a very sketchy way.

Facebook has been collecting data on teens in a very sketchy way. Stay tuned for an exclusive TechCrunch investigation

Facebook (FB) option implied volatility elevated into EPS and outlook

Facebook (NASDAQ: FB) February weekly call option implied volatility is at 88, February is at 47; compared to its 52-week range of 20 to 53 into the expected release of EPS after the bell on January 30. Call put ratio 1.4 calls to 1 put.

Facebook (FB) Integration of Messaging Services Will Be Watched by DOJ: Delrahim - Bloomberg

Facebook (NASDAQ: FB) Integration of Messaging Services Will Be Watched by DOJ: Delrahim - Bloomberg

Google, Facebook, Twitter must do more against fake news: EU

By Foo Yun Chee

BRUSSELS (Reuters) - Google, Facebook, Twitter and Mozilla must do more to combat fake news as Europeans head towards an election or the companies will face the threat of regulatory action, the European Commission said on Tuesday.

Companies and trade bodies representing the advertising industry signed up to a voluntary code of conduct in October to ward off more heavy-handed legislation. Critics say not enough has been done since they signed up.

The European Union's executive said signatories to the code of practice had taken steps to remove fake accounts and limit... More

Facebook (FB) weekly option implied volatility elevated into EPS

Facebook (NASDAQ: FB) February weekly call option implied volatility is at 79, February is at 45; compared to its 52-week range of 20 to 53 into the expected release of EPS after the bell on January 30.